News Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-02-13 EST			5-day change	1st Jan Change
17.58 ^USD	-2.66%		+2.81%	-19.14%

02-12	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-12	Sector Update: Health Care	MT

All News

02-12	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-12	Sector Update: Health Care	MT
02-12	Legend Biotech Shares Lower After Rothschild & Co Redburn Downgrade	MT
02-12	Rothschild & Co Redburn Downgrades Legend Biotech to Neutral From Buy	MT
02-06	Legend Biotech Corporation Announces Board and Audit Committee Changes, Effective February 2, 2026	CI
01-23	Legend Biotech Corporation Announces Changes to Board of Directors and Audit Committee, Effective January 20, 2026	CI
01-22	TD Cowen Downgrades Legend Biotech to Hold From Buy, Adjusts Price Target to $21 From $62	MT
01-21	Genscript Biotech Associate Books $555 Million in Q4 CARVYKTI Sales	MT
01-21	Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use	GL
01-14	Legend Biotech Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:00 AM
01-14	Legend Biotech : 2026 JP Morgan Presentation - Legend Biotech	PU
01-12	Legend Biotech highlights recent business updates at 44th annual J.P. Morgan Healthcare conference	RE
01-12	Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference	GL
01-12	Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference	AQ
01-08	RBC Cuts Price Target on Legend Biotech to $66 From $74, Keeps Outperform Rating	MT
01-07	Oppenheimer Initiates Legend Biotech at Outperform With $75 Price Target	MT
01-05	Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
12-17	Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference	GL
12-17	Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
12-10	Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says	MT
12-08	UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating	MT
12-08	Legend Biotech Corporation Highlights New CARVYKTI Data in Multiple Myeloma and First-In-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma	CI
12-06	Legend Biotech highlights new Carvykti® data in multiple myeloma and first-in-human results from novel CAR-T platform in non-Hodgkin lymphoma at ASH 2025	RE
12-06	Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025	GL
11-27	Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

All News

Filters